Jacque Duncan, MD
Ophthalmology · San Francisco, CANPI 1942252978
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,250 of the $1,290 with a category attached, or 96.9%. Bausch & Lomb Americas Inc. accounts for 96.9% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for ophthalmology clinicians in CA, where the typical reported total is $1,218.
Across 2 payments — averaging $644.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$1K
- Topcon Corporation$40
Across 50 payments — averaging $9408.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$300K
- AbbVie$167K
- Janssen Research & Development, LLC$2K
- Spark Therapeutics, Inc.$975
What the payments were for
- Speaking & faculty fees$1,25097%
- Food & beverage$403%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 1 | $1,250 |
| Topcon Corporation | 1 | $40 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,290 in reported general payments places this provider in the 50th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Brinzolamide | 22 | $4,591 |
| Dorzolamide Hcl | 29 | $479 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in San Francisco
- Daniel SchwartzSan Francisco$8M
- Gaurav ShahSan Francisco$620K
- Shan LinSan Francisco$374K
- H TanakaSan Francisco$238K
- Jay StewartSan Francisco$219K
- Scott SoSan Francisco$173K
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.